Format

Send to

Choose Destination
Leuk Lymphoma. 2008 Apr;49(4):615-9. doi: 10.1080/10428190801896103.

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.

Author information

1
CeMM-Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Abstract

Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.

PMID:
18398720
DOI:
10.1080/10428190801896103
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center